Press Release History - 2017

  • 16 Aug 2017
    New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston
  • 10 Jul 2017
    ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement
  • 15 Jun 2017
    Thomas Clay Appointed Chairman of the Board of Directors
  • 8 Jun 2017
    ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress
  • 24 May 2017
    ThromboGenics to present THR-317 Pre-clinical Research Findings at the EASDec Meeting
  • 11 May 2017
    ThromboGenics Business Update – Q1 2017
  • 2 May 2017
    New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore
  • 26 Apr 2017
    Regulated Information - Transparency Statement
  • 20 Apr 2017
    ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema
  • 16 Mar 2017
    ThromboGenics Business Update – FY 2016
  • 29 Jan 2017
    Regulated Information - Transparency Statement
  • 17 Jan 2017
    ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
  • 10 Jan 2017
    ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)